Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches-Reference-Cited by-同舟云学术

Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches

Published:2022-10-20 Issue:12 Volume:10 Page:1423-1432
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:

Author:

Läubli Heinz¹²^ORCID,Nalle Sam C.³^ORCID,Maslyar Daniel³^ORCID

Affiliation:

1. 1Laboratory for Cancer Immunotherapy, Department of Biomedicine, University, of Basel, Basel, Switzerland.

2. 2Division of Oncology, University Hospital Basel, Basel, Switzerland.

3. 3Alector, Inc., South San Francisco, California.

Abstract

Abstract The sialic acid–binding immunoglobulin-like lectin (Siglec)–sialic acid immune axis is an evolutionarily conserved immunoregulatory pathway that provides a mechanism for establishing self-recognition and combatting invasive pathogens. Perturbations in the pathway lead to many immune dysregulated diseases, including autoimmunity, neurodegeneration, allergic conditions, and cancer. The purpose of this review is to provide a brief overview of the relationship between Siglecs and sialic acid as they relate to human health and disease, to consider current Siglec-based therapeutics, and to discuss new therapeutic approaches targeting the Siglec–sialic acid immune axis, with a focus on cancer.

Funder

Swiss National Science Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Link

https://aacrjournals.org/cancerimmunolres/article-pdf/doi/10.1158/2326-6066.CIR-22-0366/3221358/cir-22-0366.pdf

Reference87 articles.

1. Siglecs: a journey through the evolution of sialic acid-binding immunoglobulin-type lectins;Bornhofft;Dev Comp Immunol,2018

2. Current status on therapeutic molecules targeting Siglec receptors;Lenza;Cells,2020

3. Role of recombination activating genes in the generation of antigen receptor diversity and beyond;Nishana;Immunology,2012